IL287962A - Combined treatments with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors - Google Patents

Combined treatments with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors

Info

Publication number
IL287962A
IL287962A IL287962A IL28796221A IL287962A IL 287962 A IL287962 A IL 287962A IL 287962 A IL287962 A IL 287962A IL 28796221 A IL28796221 A IL 28796221A IL 287962 A IL287962 A IL 287962A
Authority
IL
Israel
Prior art keywords
egfr
tyrosine kinase
kinase inhibitors
combination therapies
bispecific anti
Prior art date
Application number
IL287962A
Other languages
English (en)
Hebrew (he)
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2020/054594 external-priority patent/WO2020230091A1/en
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of IL287962A publication Critical patent/IL287962A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL287962A 2019-05-14 2021-11-09 Combined treatments with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors IL287962A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962847605P 2019-05-14 2019-05-14
PCT/IB2020/054594 WO2020230091A1 (en) 2019-05-14 2020-05-14 Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
IL287962A true IL287962A (en) 2022-01-01

Family

ID=78716450

Family Applications (1)

Application Number Title Priority Date Filing Date
IL287962A IL287962A (en) 2019-05-14 2021-11-09 Combined treatments with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors

Country Status (12)

Country Link
EP (1) EP3968985A4 (enExample)
JP (2) JP2022531980A (enExample)
KR (1) KR20220010731A (enExample)
CN (1) CN113840601A (enExample)
AU (1) AU2020275272A1 (enExample)
BR (1) BR112021022828A2 (enExample)
CA (1) CA3140360A1 (enExample)
EA (1) EA202193117A1 (enExample)
IL (1) IL287962A (enExample)
MA (1) MA55978A (enExample)
MX (1) MX2021013955A (enExample)
SG (1) SG11202112412QA (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117460714A (zh) * 2021-04-30 2024-01-26 希望之城 用于癌症治疗的pcna抑制剂和egfr抑制剂
AU2024346227A1 (en) * 2023-09-21 2026-04-09 Beijing Neox Biotech Limited Multi-specific antibodies and uses thereof
WO2025067492A1 (zh) * 2023-09-28 2025-04-03 上海翰森生物医药科技有限公司 一种双特异性抗体在制备治疗癌症的药物中的用途
CN120271706A (zh) * 2023-12-29 2025-07-08 上海安领科生物医药有限公司 抗egfr单抗、其双特异性抗体、药物组合物和用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595378B2 (en) * 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
SG188802A1 (en) * 2008-03-06 2013-04-30 Genentech Inc Combination therapy with c-met and egfr antagonists
PT2560993T (pt) * 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
US9695228B2 (en) * 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
KR102373193B1 (ko) * 2012-11-21 2022-03-10 얀센 바이오테크 인코포레이티드 이중특이성 EGFR/c-Met 항체
EP3929190B1 (en) * 2014-10-13 2024-12-25 Yuhan Corporation Compounds and compositions for modulating egfr mutant kinase activities
AR111469A1 (es) * 2017-04-21 2019-07-17 Yuhan Corp Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
MX2021010265A (es) * 2019-02-26 2021-09-23 Janssen Biotech Inc Terapias de combinacion y estratificacion de pacientes con anticuerpos anti-egfr/c-met biespecificos.

Also Published As

Publication number Publication date
BR112021022828A2 (pt) 2022-04-12
SG11202112412QA (en) 2021-12-30
JP2025118606A (ja) 2025-08-13
CA3140360A1 (en) 2020-11-19
JP2022531980A (ja) 2022-07-12
MX2021013955A (es) 2022-03-11
CN113840601A (zh) 2021-12-24
EP3968985A4 (en) 2023-07-26
EP3968985A1 (en) 2022-03-23
MA55978A (fr) 2022-03-23
EA202193117A1 (ru) 2022-02-11
KR20220010731A (ko) 2022-01-26
AU2020275272A1 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
JOP20210304A1 (ar) علاجات مركبة باستخدام الأجسام المضادة ثنائية النوعية المضادة لمستقبل عامل نمو البشرة (EGFR)/ مستقبل عامل نمو خلايا الكبد (c-Met) ومثبطات كيناز التيروسين الخاصة بمستقبل عامل نمو البشرة (EGFR) من الجيل الثالث
IL285718A (en) Combined treatments and treatment stratification with bispecific anti-egfr/c-met antibodies
SG11202112412QA (en) Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors
IL278920A (en) ENTPD2 antibodies, combination therapies, and methods of using antibodies and combination therapies
EP3889174A4 (en) BISPECIFIC HOMODIMER-TYPE ANTIBODY AGAINST HER2 AND CD3 AND USE THEREOF
IL279251A (en) Methods for treating cancer with bispecific antibodies against CD3XMUC16 and antibodies against PD-1
MY192668A (en) Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
MX2022014762A (es) Anticuerpos biespecificos contra beta amiloide humana/receptor de transferrina humano y metodos de uso.
MX2020001432A (es) Anticuerpos que se unen al receptor del factor de crecimiento epidermico (egfr) y tirosina-proteina cinasa met (cmet).
HK1202431A1 (en) Humanized pan-her antibody compositions
MY172867A (en) Bispecific egfr/c-met antibodies
MX2017004311A (es) Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos.
TN2017000470A1 (en) Heterodimeric antibodies that bind cd3 and tumor antigens.
HK1247577A1 (zh) Egfr突变阳性的非小细胞肺癌的联合疗法
SG10201912545PA (en) T cell redirecting bispecific antibodies for the treatment of egfr positive cancers
TN2019000161A1 (en) Anti-pd-1/anti-her2 natural antibody structure-like bispecific antibody of heterodimeric form and preparation thereof
IL279325A (en) Poziotinib combinations with an anti-her1, her2 or her4 antibody and methods of use thereof
HK40066572A (en) Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies
IL308225A (en) Combination therapies that include SHP2 inhibitors and EGFR tyrosine kinase inhibitors
HK40028770A (en) Compositions and methods for treating cancer with anti-egfr antibodies
EA201792249A1 (ru) Комбинированная терапия злокачественной опухоли